|

DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry

DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry
DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry

Where the worlds of psychedelics and capitalism collide, few topics have been more heavily debated than that of patents.

The most hotly argued story, of course, has been Compass Pathways’ patent behavior, which some have dubbed “patent trolling.” On top of uncertainty of whether their “proprietary” psilocybin is really unique at all, the company backed by Peter Thiel has also made claims for practices used in basically every therapy session. For example, as Shayla Love from Vice points out, one Compass patent includes clauses such as having a room “with a substantially non-clinical appearance,” with “soft furniture,” that is “decorated using muted colors,” “comprises a high-resolution sound system,” and has “a bed or a couch.”

Yea, that sounds totally fair and not at all like patent over-reach trying to own the concept of a relaxing, calm setting for psychedelic therapy.

But to think that this is a problem limited to one company would be naive. In fact, we are in something of a psychedelic patent gold rush right now, with companies sprinting to patent substances and technologies that many argue have been in the public domain for decades. Sticking with the gold rush metaphor, these bad patents could be considered fools gold, only the fools are the public who will suffer.

And now, it appears, even individuals can get in on the mad dash and start mining. 

As reported by Psilocybin Alpha’s editor-at-large, Graham Pechenik, a patent has been granted for the…ahem…“invention” of a DMT Vape Pen. The patent also covers a vape pen for 5-MeO-DMT, and 2C-B. And rather than a company being granted this right, it goes to a sole “inventor.” And it just so happens that the day job of this “inventor” is a patent lawyer. 

Now, in order to be granted a patent, there has to be no prior art, or in plain-speak, there can’t be examples of what is being patented in the public domain before the patent application was made.

And to be fair, it’s not like after a quick Google search you can find dozens of people selling DMT vape pens, albeit illegally.

Oh. Wait. 

Now, while it is easy to laugh at the ridiculousness of this patent, bad patents have serious implications for the entire psychedelics industry.

Psychedelic Spotlight has previously reported on a paper titled Patents on Psychedelics: The Next Legal Battlefront of Drug Development, in which authors argue, “Psychedelics may represent a paradigm shift for mental healthcare and the most promising solution to the mental health crisis… However, if a small number of companies secure wide swaths of intellectual property early on, then the beneficial impact of that shift may be blunted.”

For example, this patent could raise the costs for research and treatment. If it is determined that a vape pen is the best way to deliver DMT (which I am not saying it will be; intravenous administration seems to be the preferred method), then every company using DMT to treat depression or other mental health ailments will have to pay this “inventor” to use his genius “invention.” This may discourage companies from even doing research on using a vape pen in the first place and will raise the costs to consumers and patients. 

Ultimately, however, the most severe consequence of this patent is likely the precedent that it sets. It sends the message to the world that anything that exists in the psychedelics world, but is currently illegal, can be patented. 

I can guarantee that there are dozens of companies and individuals looking at the success of this patent and scanning every technology and practice that exists in the psychedelics world, looking for the next patent. 

How about mixing LSD and MDMA — also known as “candy-flipping”? Let’s patent that! Or, how about soaking LSD liquid into small pieces of paper that people can let dissolve on their tongue? I call them, “tabs.” BOOM! Patent.

Pure. Genius.

Luckily, this patent still can be challenged, though the process would be expensive, and there is no guarantee that anyone would spend the hundreds of thousands required to bring this to court.

If you believe in keeping the psychedelic space free from patent over-reach, make sure you share this article to spread the message.  

Disclaimer: Psychedelic Spotlight and its parent company, Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Similar Posts

  • My NEW Top 5 Psychedelic Stocks for 2021 || MindMed, NUMI, Atai and More

    Here are our Top 5 Best Psychedelic Stock Picks for 2021. For those who have watched our top 5 shroom stocks for 2020, you might notice that some stocks have stayed and others have been replaced because they have proven to be worthy of The Psychedelic Investor’s list by filling in the top 3 factors that we look at before investing in the psychedelic medicines industry, such as:
    Clinical Trial Progress
    Molecules & Compounds Pipeline
    The Company’s war chest to sustain growth as a biotech company in a new industry

    But why invest in psychedelic stocks?
    Ever since last year, celebrity investors such as Kevin O’Leary and Peter Thiel decided to invest in the psychedelic/ shroom stocks industry, the industry grew from 2 or 3 companies to approximately 30 in 2021. This is probably one of the main reasons why we call this phenomenon the SHROOM BOOM!
    But why do such investors seem to believe so much in the potential explosive growth of psychedelic stocks?
    1. Psychedelics have been shown in many recent clinical trials to help a variety of mental health issues, from addiction, to depression to PTSD and more.
    2.These psychedelic companies are attempting to disrupt the 100 billion annual industry for mental health pharmaceuticals.
    3.These psychedelic compounds have the potential to help millions world wide, this also presents an amazing opportunity for early investors.
    4.Smart investors might realize that rather than going all in on one company in the field, it is probably best to diversify your risk and create a Psychedelic Medicines portfolio.

    So our top 5 Shroom Stock Pics for 2021 are:
    5. Cybin ( CYBN on NEO & CLXPF on the OTC)
    4. Numinus Wellness (LKYSF on the OTC & NUMI on the TSX)
    3. Compass Pathways (CMPS on Nasdaq)
    2. Atai Life Sciences – Soon to IPO on the Nasdaq
    1 Mind Medicine or MindMed (MMED on NEO MNMD on Nasdaq & MMQ on FRA)
    Link to Cybin (CYBN) : https://www.cybin.com/
    Link to Numinus (NUMI) : https://numinus.ca/
    Link to Compass Pathways (CMPS) : https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
    Link To Atai life Sciences: https://www.atai.life/
    Linke To MindMed (MMED / MNMD / MMQ) https://mindmed.co/

    Timestamps:
    0:00 – Intro
    1:58 – Ranking criteria
    3:42 – Cybin (CYBN) ( CLXPF)
    6:24 – Numinus Wellness ( NUMI)
    10:04 – Compass Pathways (CMPS)
    13:52 – Atai Life Sciences
    18:50 – MindMed ( MMED / MNMD/ MMQ )

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    Clinical trials :

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #CMPSStock